Docosapentaenoic acid.

Elongase 2 and elongase 5 extend EPA by two carbons to give n-3 DPA, which is the obligatory intermediate on the route from EPA to DHA. n-3 DPA also retroconverts to EPA through beta-oxidation, which means supplementing it raises circulating EPA as well. That two-way traffic is the defining feature of this fatty acid. It behaves as a reservoir that feeds both directions.

To reach DHA, n-3 DPA is elongated to a 24-carbon intermediate, desaturated, and then shortened by one beta-oxidation cycle in the peroxisome. That final step is the bottleneck in humans, which is why conversion beyond n-3 DPA is limited. Supplementing n-3 DPA raises DPA and EPA reliably and DHA far less. The order of the pathway explains the pattern.

Most fish oil labels quantify only EPA and DHA even though a few percent of the oil is n-3 DPA. On top of that, the EPA delivered is partly elongated to DPA in the body. Someone already taking a marine oil is getting more of this fatty acid than the label states. That is worth knowing before adding a separate DPA product.

n-3 DPA is present at low single-digit percentages in most fish oils and at higher proportions in some marine mammal oils. It arrives as part of the triglyceride mixture rather than as an isolated compound. Because it is not usually quantified, intake from this route is invisible on a label. Total marine omega-3 intake is the more meaningful number.

Alpha-linolenic acid is desaturated and elongated toward EPA and then n-3 DPA. Conversion efficiency in humans is low, in the low single digits for EPA and lower still beyond it, and it is further suppressed by high linoleic acid intake. Plant sources therefore raise n-3 DPA far less than marine sources do. This is why relying on flaxseed for long-chain omega-3 status generally does not work.

Delta-6 desaturase acts on both linoleic acid and alpha-linolenic acid, and the larger pool wins by mass action. A diet heavy in omega-6 oils therefore suppresses conversion along the omega-3 route where n-3 DPA sits. Lowering linoleic acid intake raises the efficiency of the same enzymes for the omega-3 substrate. The competition is enzymatic, not absorptive.

With five double bonds, n-3 DPA oxidises readily both in the container and in the body. Tocopherol interrupts the peroxyl radical chain that drives that oxidation. Marine oil products add tocopherol as standard for shelf stability. The same chemistry applies to the fatty acid once it is in the membrane.

Astaxanthin partitions into the membrane and quenches reactive oxygen species there, which limits peroxidation of long-chain polyunsaturated fatty acids. The pairing comes from krill oil's natural composition rather than from a trial testing the two together. The described benefit is oxidative stability, not any measured clinical outcome. Read it as formulation rationale.

Krill oil delivers a share of its omega-3 fatty acids esterified to phospholipids rather than triglycerides, which follows a somewhat different absorption route. n-3 DPA is present as a minor component in that mixture. Whether the phospholipid vehicle changes DPA incorporation specifically has not been established. The vehicle question and the fatty acid question are separate.

Long-chain omega-3 fatty acids are largely stored esterified at the sn-2 position of membrane phospholipids, and phosphatidylcholine is the most abundant of those. Phospholipid delivery formats exist for exactly this reason. This describes the transport and storage chemistry rather than a tested combination. The fatty acid ends up in the same place regardless of the vehicle it arrived in.